Race Oncology

Race Oncology (ASX: RAC) Executive Director Dr Peter Smith will be presenting at the inaugural HealthInvest summit in Sydney on 18 September 2024, hosted by IR Department, Morgans Financial Limited and Stockhead. Pete will provide a detailed update on Race’s lead drug #bisantrene, a unique asset carrying great clinical and commercial potential For more information and to register for the event, please visit www.healthinvestlive.com #HealthInvest #lifesciences #cardioprotection

At Race Oncology, #CancerResearch is at the heart of everything we do.   This #DaffodilDay, we stand with Cancer Council Australia in their mission to fund research that could lead to breakthroughs, such as #bisantrene, improving patient outcomes, and, ultimately, a world where cancer is no longer a life-defining diagnosis.   Discover more: https://shorturl.at/xBNEz   #HopeBlooms #CancerAwareness #InnovationInCancerCare

The Breast Cancer Trials Group recently hosted a Q A webinar focusing on heart health in breast cancer treatment. This informative webinar features perspectives from a multidisciplinary panel of experts involved in the oncology treatment process, as well as Lee Hunt, a patient who courageously shared her story of going through breast cancer treatments and battling against heart failure post treatment.   Professor Aaron Sverdlov, cardiologist from the University of Newcastle, commented in this session that incorporating cardiovascular health into the communication between specialist groups is paramount to treating cancer. Monitoring symptoms of experiencing cardiac toxicity is critical and they are often detectable 12 months post treatment.   Thank you to the Breast Cancer Trial Group for shedding light on this important topic. You can watch the full Q A session via this link: https://lnkd.in/gZ-GB_ZU #cardiotoxicity #cancertreatment #bisantrene

Today, we join Cancer Nurses Society Of Australia (CNSA) to celebrate the inaugural #CancerNurseDay.    Cancer care is a challenging area of practice. Race Oncology would like to take this opportunity to acknowledge the 7500 cancer nurses across the country, whose work is pivotal in improving patient outcomes in the complex and ever-shifting healthcare landscape.    #OncologyCare #CancerTreatment #CardioProtection

Race Oncology is pleased to be featured in Stockhead’s FY2025 Investor Guide: Health and Biotech. The Investor Guide showcases strong forces from the Australian health and biotech sector, offering deep insights to ASX investors.    In this feature, Race CEO Dr Daniel Tillett shares the company’s journey of discovering and developing lead asset #bisantrene, a unique drug for its anticancer and cardioprotective properties. Dr Tillett also notes that the company is well positioned financially for its clinical pipeline.   Read the full Guide via this link: https://lnkd.in/gppgdwNK   #oncologytreatment #cardioprotection #biotechinvestment

Race Oncology was pleased to attend the TechKnow Invest Roadshow last week, with CEO Dr Daniel Tillett and Executive Director Dr Peter Smith presenting at Sydney and Melbourne conferences respectively.    It was encouraging to see our peers from the biotech sector demonstrating outstanding clinical progress, and even better communicating this to a cohort of engaged life science investors.    Thank you Vertical Events for organising this Roadshow and thank you to all who took the time to speak with us at our kiosk.    #BiotechInvestment #lifescience

The Australian reports the conclusion of Race Oncology’s Phase 1b/2 trial of bisantrene RC110 in acute myeloid leukaemia (AML) patients. Results show that 40% of relapsed or refractory AML patients showed responses to #bisantrene, in combination with clofarabine and fludarabine, marking the trial achieving its primary endpoint for efficacy.   In an interview with Stockhead, Race CEO Dr Daniel Tillett said: “These were very advanced patients, with weeks of life expectancy when they came onto the trial. The trial showed excellent results in a very difficult-to-treat patient population. If this result was repeated in a Phase 3 trial, it would be an approvable result.”   To read the full report, including a video interview with Dr Tillett, visit Race’s Investor Hub via this link:  https://lnkd.in/ga4N4q3P   #carodioprotection #oncologytreatment

Race Oncology is pleased to announce that the investigator-sponsored Phase 1b/2 trial of #bisantrene has been successfully concluded, with the results showing that bisantrene, used in combination with clofarabine and fludarabine (Bis/Clo/Flu) in relapsed or refractory acute myeloid leukaemia (R/R AML) patients, has achieved its primary endpoint for efficacy.   The trial was conducted at the Sheba Medical Center, Tel Hashomer in Israel under the supervision of AML key opinion leader Professor Arnon Nagler. In patients with highly advanced disease, 40% showed a response to bisantrene combination treatment, surpassing the trial's predefined efficacy goal of at least 3 complete responses. Findings strongly support Race's intention to initiate a new Phase 1/2 investigator-sponsored AML trial using the new formulation of bisantrene #RC220.   Race Oncology CEO, Dr Daniel Tillett said: “I would like to extend my sincere thanks to Professor Nagler and his dedicated team at the Chaim Sheba Medical Centre Their dedication and commitment has added to the strong historical evidence of bisantrene’s efficacy in treating patients with AML, and has stimulated further clinician interest in taking the drug forward in new AML trials. We extend our gratitude to all patients and their families whose participation makes the development of new AML treatments such as bisantrene possible.”   “Race has plans to support a new Phase 1/2 investigator-sponsored AML clinical study using RC220 bisantrene and will provide an update as soon as all relevant contracts are concluded.”   Read the full announcement on Race’s Investor Hub page: https://shorturl.at/gz1FU #cardioprotection #oncologytreatment

Race Oncology’s (ASX: RAC) Executive Director, Dr Peter Smith presented on Friday 12 July to industry investors, brokers and colleagues at the 18th Bioshares Biotech Summit, in Fremantle, WA. During the session on Repurposing Existing Pharmaceuticals, Dr Smith explained the impacts of cardiovascular toxicity caused by oncology therapies and how it can affect patients’ lives post treatment. #BiotechSummit2024 #investors 

We are pleased to share that Race Oncology will present at the #Bioshares2024 conference at the Esplanade Hotel in Perth, Western Australia this week.    Race Executive Director, Dr Peter Smith will present at Session 4: Repurposing Existing Pharmaceuticals, this Friday July 12 2024 from 5.30 to 5.50pm.   During his presentation, Dr Smith will cover cardiovascular toxicity in oncology treatment and how it impacts patients’ lives post treatment. He will also discuss the clinical history of Race’s lead asset #bisantrene and development the new RC220 bisantrene formulation.    We look forward to meeting the attendees at the conference. For more on the Bioshares 2024 conference: https://lnkd.in/eDFqeT-y   #Bioshares #biotechinvestment #cardioprotection #oncology